Celera Gets $900K From NIH to Develop Avian Flu Dx; Abbott to Sell Assay | GenomeWeb
NEW YORK (GenomeWeb News) – Celera Genomics today said it has received $900,000 from the US National Institutes of Health to develop and commercialize an in vitro diagnostic for detect the A/H5 influenza virus.
 
Celera said it plans to develop the test using the primer, probe set, and protocols used by US Health and Human Services' Centers for Disease Control and Prevention, whose IP was recently cleared by the US Food and Drug Administration.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.